/prueba%202.jpg)
/button545.gif){kind=small}
/button546.gif){kind=small}
/button19B1.gif){kind=small}
/button19E1.gif){kind=small}
/button1A7.gif){kind=small}
/button1A10.gif){kind=small}
/button1AA.gif){kind=small}
/button1AD.gif){kind=small}
EspañolnMost recent publications
Year
Publication
2012 Bañez-Coronel, M., Porta, S., Kagerbauer, B., Mateu-Huertas, E., Pantano, L., Ferrer, I., Guzmán, M., Estivill, X., Martí, E. (2012) A pathogenic mechanism in Huntington´s disease involves small CAG- Repeated RNAs with neurotoxic activity. PLoS Genet 8 (2). 2 MB
2012 Velasco, G., Sánchez, C., Guzmán, M. (2012) Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer. AOP. May 4; 12 (6): 436-44. 2012 Pérez-Gómez, E., Andradas, C., Flores, JM., Quintanilla, M., Paramio, JM., Guzmán, M., Sánchez, C. (2012) The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carciomas. Oncogene (2012), 1-9. 2012 Caffarel, M., Andradas, C., Pérez-Gómez, E., Guzmán, M., Sánchez,C. (2012) Cannabinoids: A new hope for breast cancer therapy?. Cancer Treatment Reviews. 38 (7), 911-8. 2012 Palazuelos, J., Ortega, Z., Díaz-Alonso, J., Guzmán, M., Galve-Roperh, I. (2012) CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1
signaling. J. Biol. Chem. 287, 1198-1209.2011 Henstridge, CM., Balenga, NA., Kargl, J., Andradas, C., Brown, AJ., Irving, A., Sanchez, C., Waldhoer, M. (2011) Recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol. 11:1835-1848 2011 Salazar, M., Hernández-Tiedra, S., Torres, S., Lorente, M., Guzmán, M., Velasco, G. (2011) Detecting autophagy in response to ER stress signals in cancer. Methods Enzymol. 489, 297-317.
2011 Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I.(2011) Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ.18, 1099-111 2011 Lorente, M., Torres, S., Salazar, M., Carracedo, A., Hernández-Tiedra, S., Rodríguez-Fornés, F., García-Taboada, E., Meléndez, B., Mollejo, M., Campos-Martín, Y., Lakatosh, S.A., Barcia, J., Guzmán, M., Velasco, G. (2011) Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy mediated cell death. Autophagy 7, 1071-1073.
2011 Lorente, M., Torres, S., Salazar. M., Carracedo, A., Hernández-Tiedra, S., Rodríguez-Fornés, F., García-Taboada, E., Meléndez, B., Mollejo, M., Campos-Martín, Lakatosh, Y., Barcia, J., Guzmán, & Velasco, G. (2011) Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ. 18, 959-73.
2011 Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S.,Salazar. M., García-Taboada, E., Barcia, J., Guzmán, M., & Velasco, G. (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 10, 90-103
2011 Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M.R, Resel, E., Palazuelos. J., Julien, B., Salazar, M., Börner, C., Benito, C., Carrasco, C., Diez-Zaera, M., Paoletti, P., Díaz-Hernández, M., Ruiz, C., Sendtner, M., Lucas, J.J., De Yébenes, J.G., Marsicano, G., Monory, K., Lutz, B., Romero, J., Alberch, J., Ginés, S., Kraus, J., Fernández-Ruiz, J., Galve-Roperh, I., Guzmán, M. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119-136 2011 Andradas, C., Caffarel, M.M., Pérez-Gómez E., Salazar M. , Lorente M., Velasco G., Guzmán, M., Sánchez C. (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30 (2), 245-252
2010 Caffarel, M.M , Andradas, C., Mira, E., Pérez-Gómez, E., Cerutti, C., Moreno-Bueno, G., Flores, J. M., García-Real, I., Palacios, J., Mañes, S., Guzmán, M., Sánchez, C. (2010) Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol. Cancer 9, 196-197
2010 Guzmán, M. (2010) A new age for MAGL. Chem. Biol. 17, 4-6 2010 Barana, A., Amorós, I., Caballero, R., Gómez, R., Osuna, L., Lillo, M.P., Blázquez, C., Guzmán, M., Delpón, E. & Tamargo, J. (2010) Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. Cardiovasc. Res. 85, 56-67 2009 Palazuelos, J., Aguado, T., Pazos, M.R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., Fernández-Ruiz, J., Guzmán, M., Galve-Roperh, I. (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington´s disease excitotoxicity. Brain 132, 3152-3164 2009 Oesch, S., Walter, D., Wachtel, M., Pretre, K., Salazar, M., Guzmán, M., Velasco, G., Schäfer, B.W. (2009) Cannabinoid receptor 1 is a potential drug targefor treatment of translocation-positive rhabdommyosarcoma. Mol. Cancer Ther. 8, 1838-1845 2009 Lorente, M., Carracedo, A., Torres, S., Natali, F., Egia, A., Blázquez, C., Hernández, S., Guzmán, M., Velasco, G. (2009) Amphiregulin renders glioma cells resistant to cannabinoid-induced apoptosis. Glia 57, 1374-1385 2009 Galve-Roperh, I., Palazuelos, J., Aguado, T., Guzmán, M. (2009) The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders. Eur. Arch. Psych. Neurosci. 259, 371-382 2009 Salazar, M., Carracedo, A., Salanueva, I., Hernández, S., Blázquez, C., Lorente, M., Egia, A., Vázquez, P., Torres, S., Nowak, J., Fimia, G.M., Piacentini, M., Cecconi, F., Pandolfi, P.P., González-Feria, L., Iovanna, J.L., Guzmán, M., Boya, P., Velasco, G. (2009) Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119, 1359-1372 2008 Galve-Roperh, I., Aguado, T., Palazuelos, J., Guzmán, M. (2008) Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des. 14, 2279-2288 2008 Caffarel, M.M., Moreno-Bueno, G., Cerutti, C., Palacios, J., Guzmán, M., Mechta-Grigoriou, F., Sánchez, C. (2008) JunD is involved in the antiproliferative effect of Δ9-tetrahydrocannabinol on human breast cancer cells. Oncogene 27, 5033-5044 2008 Mulder, J., Aguado, T., Barabás, K., Ballester-Rosado, C.J., Nguyen, L., Monory, K., Keimpema, E., Marsicano, G., Di Marzo, V., Hurd, Y.L., Guillemot, F., Mackie, K., Lutz, B., Guzmán, M., Chen Lu, H.M., Galve-Roperh, I., Harkany, T. (2008) Endocannabinoid signaling is indispensable for pyramidal cell specification and corticothalamic axon patterning. Proc. Natl. Acad. Sci. USA 105, 8760-8765 2008 Palazuelos, J., Davoust, N., Julien, B., Hatterer, E., Aguado, T., Mechoulam, R., Benito, C., Romero, J., Silva, A., Guzmán, M., Nataf, S., Galve-Roperh, I. (2008) The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 283, 13320-13329 2008 Blázquez, C., Salazar, M., Carracedo, A., Lorente, M., Egia, A., González-Feria. L., Haro, A., Velasco, G. & Guzmán, M. (2008) Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 68, 1945-1952 2008 Blázquez, C., Carracedo, A., Salazar, M., Lorente, M., Egia, A., González-Feria. L., Haro, A., Velasco, G. & Guzmán, M. (2008) Down- regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology 54, 235- 243 2007 Velasco, G., Carracedo, A., Blázquez, C., Lorente, M., Aguado, T., Haro, A., Sánchez, C., Galve-Roperh, I. & Guzmán, M. (2007) Cannabinoids and gliomas. Mol. Neurobiol. 36, 60-67 2007 Harkany, T. Guzmán, M., Galve-Roperh, I. Berghuis, P., Devi, L. & Mackie, K. (2007) The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol. Sci. 28, 83-92 2007 Galve-Roperh, I., Aguado, T., Palazuelos, J. & Guzmán, M. (2007) The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13, 109-114 2007 Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R.M., Ramos, J.A. & Guzmán, M. (2007) Cannabinoid CB2 receptor: a new target for the control of neural cell survival? Trends Pharmacol. Sci. 28, 39-45 2007 Aguado, T., Romero, E., Monory, K., Sendtner, M., Marsicano, G., Lutz, B., Guzmán, M. & Galve-Roperh, I. (2007) The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem 282, 23892-23898 2007 Aguado, T., Carracedo, A., Julien, B., Velasco, G., Milman, G., Mechoulam, R., Álvarez, L., Guzmán, M. & Galve-Roperh, I. (2007) Cannabinoids inhibit glioma stem-like cell differentiation and inhibit gliomagenesis. J. Biol. Chem. 282, 6854-6862 2006 Galve-Roperh, I., Aguado, T., Rueda, D., Velasco, G. & Guzmán, M. (2006) Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. Curr. Pharm. Des. 12, 2319-2325 2006 Blázquez, C., Carracedo, A., Barrado, L., Real, P.J., Fernández-Luna, J.L., Velasco, G., Malumbres, M. & Guzmán, M. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633-2635 2006 Palazuelos, J., Aguado, T., Egia, A., Mechoulam, R., Guzmán, M. & Galve-Roperh, I. (2006) Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 20, 2405-2407 2006 Lo Verme, J., Guzmán, M., Gaetani, S. & Piomelli, D. (2006) Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue. J. Biol. Chem. 281, 22815-22818 2006 Guzmán, M., Duarte, M.J., Blázquez, C., Ravina, J., Rosa, M.C., Galve- Roperh, I., Sánchez, C., Velasco, G. & González-Feria, L. (2006) A pilot clinical study of D9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer 95, 197-203 2006 Carracedo, A., Gironella, M., Lorente, M., Garcia, S., Guzmán, M., Velasco, G. & Iovanna, J.L. (2006) Antitumoral effect of cannabinoids on pancreatic cancer. Cancer Res. 66, 6748-6755 2006 Caffarel, M.M., Sarrió, D., Palacios, J., Guzmán, M. & Sánchez, C. (2006) D9-tetrahydrocannabinol inhibits human breast cancer cell cycle by down- regulating Cdc2. Cancer Res. 66, 6615-6621 2006 Kogan, N.M., Blázquez, C., Álvarez, L., Gallily, R., Schlesinger, M., Guzmán, M. & Mechoulam, R. (2006) A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol. Pharmacol. 70, 51-59 2006 Herrera, B., Carracedo, A., Diez-Zaera, M., Gómez del Pulgar, T., Guzmán, M. & Velasco, G. (2006) The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp. Cell Res. 312, 2121-2131 2006 Carracedo, A., Lorente, M., Egia, A., Blázquez, C., Garcia, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., González-Feria, L., Piris, M.A., Iovanna, J.L., Guzmán, M. & Velasco, G. (2006) The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301-312 2006 Carracedo, A., Egia, A., Guzmán, M. & Velasco, G. (2006) p8 sensitizes astrocytes to oxidative stress. FEBS Lett. 580, 1571-1575 2006 Aguado, T., Palazuelos, J., Monory, K., Stella, N., Cravatt, B., Lutz, B., Marsicano, G., Kokaia, Z., Guzmán, M. & Galve-Roperh, I. (2006) The endocannabinoid system promotes astroglial differentiation by acting on neural progenitors. J. Neurosci. 26, 1551-1561 2005 Velasco, G., Galve-Roperh, I., Sánchez, C., Blázquez, C., Haro, A. & Guzmán, M. (2005) Cannabinoids and ceramide: two lipids acting hand- by-hand. Life Sci. 77, 1723-1731 2005 Herrera, B., Carracedo, A., Diez-Zaera, M., Guzmán, M. & Velasco, G. (2005) p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukemia cells. FEBS Lett. 579, 5084-5088 2005 Aguado, T., Monory, K., Palazuelos, J., Stella, N., Cravatt, B., Lutz, B., Marsicano, G., Kokaia, Z., Guzmán, M. & Galve-Roperh, I. (2005) The endocannabinoid system drives neural progenitor proliferation. FASEB J. 19, 1704-1706 2005 Ramírez, B.G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M. & de Ceballos, M.L. (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913
 |
/dots.jpg)
|
|
/NSF.jpg)
Our group acknowledges the support of public funding institutions, both national (Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III - CIBERNED) and local (Comunidad de Madrid, Universidad Complutense de Madrid), as well as private funding institutions (GW Pharmaceuticals, Schering-Plough, Fundación de Investigación Médica Mutua Madrileña)
